Search

Search Results

• PO-44 | Effectiveness of fremanezumab as preventive treatment of migraine up to 24 months: response rates from the Italian analysis of the PEARL study Alberto Doretti,¹ Anna Ambrosini,² Simone Braca,³ Florindo D’Onofrio,⁴ Elisa Maria Piella,⁵ Pinar Kokturk,⁶ Rosario Iannacchero⁷ | ¹Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; ²Mediterranean Neurological Institute NEUROMED IRCCS, Pozzilli (IS), Italy; ³Headache Centre, University of Naples “Federico II”, Naples, Italy; ⁴UOSD Stroke Unit, S.G. Moscati Hospital, Avellino, Italy; ⁵Neurosciences Department, University of Turin, Turin, Italy; ⁶Teva Netherlands B.V., Haarlem, The Netherlands; ⁷Department of Neurology, Headache Center, Regional Hospital “Pugliese-Ciaccio”, Catanzaro, Italy

  Società Italiana per lo Studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15866

  162

• PO-62 | Preventive migraine treatment in patients under 25: a 24-month observational study on adherence, therapeutic switching, and prescription determinant factors Marilena Marcosano,¹ Nicoletta Brunelli,¹ Luisa Fofi,¹ Laura Papetti,² Fabiana Ursitti,² Massimiliano Valeriani,² Fabrizio Vernieri,¹ Claudia Altamura¹ | ¹Headache and Neurosonology Unit, Fondazione Policlinico Campus Biomedico di Rome, Rome, Italy; ²Developmental Neurology, Bambino Gesù Children Hospital, IRCCS, Rome, Italy

  Società Italiana per lo studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15885

  145

• PO-16 | Neurophysiological effects of atogepant in high-frequency episodic migraine B. Agostini,^1,2 F. Cammarota,^1,2 R. De Icco,^1,2 V. Grillo,^1,2 G. Vaghi,^1,2 F. Bighiani^1,2, M. Corrado,² A. Antoniazzi,^1,2 M. Giraudo,^1,2 A. Solfrizzi,^1,2 R. Greco,² C. Demartini,^1,2 A. Zanaboni,^1,2 M. Francavilla,^1,2 S. Facchetti,^1,2 G. Sances,² C. Tassorelli^1,2 | ¹Department of Brain and Behavioral Sciences, University of Pavia; ²Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy

  Società Italiana per lo Studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15837

  227

• PO-79 | Survey on adherence and tolerability of atogepant used as migraine preventive treatment D.A. Montisano,¹ G. Vaghi,^2,3 A. Paris,¹ R. De Icco,^2,3 B. Agostini,^2,3 M. Giraudo,^2,3 A. Solfrizzi,^2,3 C. Tassorelli,^2,3 G. Sances,³ L. Grazzi | ¹Fondazione IRCCS C.Besta Istituto Neurologico, SSD Headache Center, Milan, Italy; ²University of Pavia, Department of Brain and Behavioral Sciences, Pavia, Italy; ³IRCCS Mondino Foundation, Headache Science & Neurorehabilitation Unit, Pavia, Italy

  Società Italiana per lo Studio delle Cefalee (SISC)

  06-11-2025

  https://doi.org/10.4081/cc.2025.15903

  260